Boehringer Ingelheim to Present New Data on PGx NSCLC Drug Afatinib at ASCO Annual Meeting

In preliminary studies, "researchers observed a tumor size reduction of up to 76 percent over a treatment period of up to five months" in patients who had acquired resistance to standard tyrosine kinase inhibitors.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.